- Home
- DYAI vs RVPH Comparison
DYAI vs RVPH Comparison
Compare DYAI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- RVPH
- Stock Information
- Founded
- DYAI 1979
- RVPH 2006
- Country
- DYAI United States
- RVPH United States
- Employees
- DYAI N/A
- RVPH N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- RVPH Health Care
- Exchange
- DYAI Nasdaq
- RVPH Nasdaq
- Market Cap
- DYAI 28.3M
- RVPH 32.8M
- IPO Year
- DYAI 2004
- RVPH N/A
- Fundamental
- Price
- DYAI $1.00
- RVPH $0.40
- Analyst Decision
- DYAI Strong Buy
- RVPH Strong Buy
- Analyst Count
- DYAI 1
- RVPH 5
- Target Price
- DYAI $6.00
- RVPH $9.00
- AVG Volume (30 Days)
- DYAI 63.2K
- RVPH 3.8M
- Earning Date
- DYAI 08-12-2025
- RVPH 08-13-2025
- Dividend Yield
- DYAI N/A
- RVPH N/A
- EPS Growth
- DYAI N/A
- RVPH N/A
- EPS
- DYAI N/A
- RVPH N/A
- Revenue
- DYAI $3,554,344.00
- RVPH N/A
- Revenue This Year
- DYAI $22.56
- RVPH N/A
- Revenue Next Year
- DYAI $30.95
- RVPH N/A
- P/E Ratio
- DYAI N/A
- RVPH N/A
- Revenue Growth
- DYAI 57.59
- RVPH N/A
- 52 Week Low
- DYAI $0.91
- RVPH $0.30
- 52 Week High
- DYAI $2.20
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- DYAI 46.85
- RVPH 36.63
- Support Level
- DYAI $0.91
- RVPH $0.38
- Resistance Level
- DYAI $1.02
- RVPH $0.45
- Average True Range (ATR)
- DYAI 0.05
- RVPH 0.04
- MACD
- DYAI 0.01
- RVPH 0.01
- Stochastic Oscillator
- DYAI 35.07
- RVPH 58.54
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.